Four Dental Experts Join Oragenics' International Scientific Advisory Board

Oragenics, Inc. (Amex:
ONI) announces that Dr. Raman Bedi, Chairman of Oragenics' International
Scientific Advisory Board, has enlisted four global dental experts to join
Oragenics' International Scientific Advisory Board: Dr. Ayyaz Khan of
Pakistan, Dr. Brian Mouatt of the United Kingdom, Dr. Hari Parkash of India
and Dr. Eli Schwarz of Australia. Dr. Bedi is the former Chief Dental
Officer of England, recipient of the Foundation chair in Transcultural
Health at University College London, a recipient of the first annual Asian
Power 100 list, as well as numerous other accomplishments in the area of
oral health worldwide. Dr. Khan is the most senior dental advisor to the
Health Ministry in Pakistan. He is currently the Head of the Department of
Oral Health Sciences at Shaikh Zayed Medical Center in Lahore, Pakistan and
is the National Coordinator for Oral Health for a Joint WHO/Government of
Pakistan Program. Dr. Mouatt served as the 5th Chief Dental Officer for
England and previously served as the Chief Dental Officer for Zambia. He is
the past chair of the International Dental Federation (FDI) World Dental
Development Health Promotion Committee and the current President of the
Commonwealth Dental Association. Dr. Parkash is one of the most senior
dental advisors to the federal government of India and is currently the
Director for ITS Center Dental Studies and Research, Ghaziabad, (U.P.)
India. In addition, Dr. Parkash has served as Project Director, National
Oral Health Care Program of India, Ministry of Health and Family Welfare,
Past President, Int. Coll. of Dent. (India & Sri Lanka Sect.). Dr. Schwarz
served as the Chief Dental Officer of Denmark, and served in the National
Board of Health, Copenhagen Denmark. Dr. Schwarz's distinguished career
includes being conferred the Royal Order, Knight of the Order of Dannebrog,
by Her Majesty Queen Margrethe II of Denmark. Currently, he is Professor
and Dean at the Faculty of Dentistry at the University of Sydney,
Australia.


"To have Dr. Bedi agree to Chair our International Scientific Advisory
Board and to have four dental experts of such prominence as Drs. Khan,
Mouatt, Parkash, and Schwarz consent to serve on the Board is quite an
honor for Oragenics," said "Dr. Zahradnik, Oragenics' Chief Executive
Officer. "We are excited about working with these five past-Chief Dental
Officers on a global strategy for advancing our technologies through
clinical trials, partnering, and commercialization.


"Oragenics is a global company with products that will dramatically
influence the health of everyone. We have reflected this global dimension
with our selection of international advisors. It is a privilege to lead
such internationally renowned scientists and dental leaders. Interest in
Oragenics' potential has arisen from both investors and scientists across
four continents. Within this calendar year we should have demonstrated the
clinical effectiveness of a dental product which will transform the oral
hygiene industry," said Raman Bedi.















The advisory group has begun identifying strategic alliances in Asia
and Middle East. These efforts by the International Scientific Advisory
Board are expected to result in a global strategy for conducting clinical
trials for SMaRT Replacement Therapy(TM). Oragenics currently plans to
initiate multi- center clinical trials outside the United States in early
to mid-2007, once regulatory approval is received.


On an unrelated matter, a study is currently being conducted for
Oragenics' cosmetic mouth rinse product, Probiora3(TM), to substantiate the
claim that it helps maintain a healthy beneficial bacteria in the human
mouth. The first subjects have been enrolled and upon completion of the
study in September, Oragenics will finalize the selection of partners for
commercialization of this unique oral probiotic product.



About Oragenics


Oragenics, Inc. is a biopharmaceutical company with a pipeline of
proprietary technologies. The Company has a number of products in
discovery, preclinical and clinical development, with a concentration in
two main therapeutic areas: infectious disease and oncology. Oragenics'
core pipeline includes products for use in the treatment of dental and
periodontal infectious diseases, systemic bacterial infections and obesity.
In the discovery stage are three platform technologies for identifying
biomarkers of infection, cancer and autoimmune diseases and for the solid
state synthesis of bioactive peptides including small molecule antibiotics.


Safe Harbor Statement: Under the Private Securities Litigation Reform
Act of 1995. This release includes forward-looking statements that reflect
Oragenics' current views with respect to future events and financial
performance. These forward-looking statements are based on management's
beliefs and assumptions and information currently available. The words
"believe," "expect," "anticipate," "intend," "estimate," "project" and
similar expressions that do not relate solely to historical matters
identify forward- looking statements. Investors should be cautious in
relying on forward-looking statements because they are subject to a variety
of risks, uncertainties and other factors that could cause actual results
to differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to those set forth
in our most recently filed annual report on Form 10-KSB and quarterly
report on Form 10-QSB and other factors detailed from time to time in
filings with the Securities and Exchange Commission. We expressly disclaim
any responsibility to update forward-looking statements.


For more information about Oragenics, please consult the company's
website at oragenics.


Oragenics, Inc.

oragenics